Incidence and risk factors of bleeding-related adverse events in patients with chronic lymphocytic leukemia treated with ibrutinib

Disclosures: Pharmacyclics provided ibrutinib and research support. AW has served as an unpaid consultant/advisory board member for Pharmacyclics.

Contributions: MF and AW conceived and designed the study. SS coordinated sample collection. KN and AC performed platelet function assays. JV, CUN, CS, SEMH, NS, GM, GU, SH, and AHL were involved in planning and supporting components of the research. MF, SM, and AHL collected and assembled data. JL interpreted platelet aggregation studies. AHL analyzed the data, generated figures, and performed literature review. AHL and XT conducted multivariate analysis. AHL, AW and SM wrote the manuscript. JL and AW supervised the project and approved the final version of the manuscript.